Scholarlink

Background <p>Therapeutic options are limited for patients with high-grade ovarian carcinoma (HGOC) progressing after poly(adenosine diphosphate-ribose) polymerase-inhibitor (PARPi). WEE1/CDK2-inhibitors efficacy is under investigation in HGOC harbouring <i>CCNE1</i> amplification/Cyclin E1 overexpression. However, Cyclin E1 expression evolution after PARPi has not been studied. We aimed to describe Cyclin E1 expression/<i>CCNE1</i> copy number in post-PARPi HGOC samples and compare to paired samples from diagnosis and/or post-neoadjuvant chemotherapy (post-NACT).</p> Methods <p>Thirty-eight patients with available post-PARPi samples were included; paired samples from diagnosis (<i>n</i> = 26) and/or post-NACT (<i>n</i> = 24) were collected. Cyclin E1 expression was quantified using immunohistochemistry (IHC). <i>CCNE1</i> copy number was evaluated using fluorescent in situ hybridisation (FISH).</p> Results <p>Seventy-two percent (26/36) of HGOC were homologous recombination deficient. Intratumoral Cyclin E1 expression was homogenous in samples from synchronous but anatomically distinct tumour sites. However, Cyclin E1 expression increased significantly between diagnosis and progression post-PARPi (median H-score = 113 <i>versus</i> 163, respectively; <i>p</i> = 0.034). The proportion of Cyclin E1-high (H-score ≥ 150) tumours was 31% (8/26) at diagnosis, 42% (10/24) post-NACT, and increased significantly to 61% (23/38) post-PARPi (<i>versus</i> diagnosis; <i>p</i> = 0.024). In contrast, only 10% (2/20) of Cyclin E1-high HGOC exhibited <i>CCNE1</i> amplification ( ≥ 8 <i>CCNE1</i> copies).</p> Conclusions <p>Cyclin E1 expression in HGOC increases at post-PARPi progression, independently of <i>CCNE1</i> amplification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Alexis Trecourt,
  • Alexander Valent,
  • Elisa Yaniz-Galende,
  • Etienne Rouleau,
  • Juan Francisco Grau Bejar,
  • Félix Blanc-Durand,
  • Elodie Edmond,
  • Audrey Le Formal,
  • Catherine Genestie,
  • Alexandra Leary

摘要

Background

Therapeutic options are limited for patients with high-grade ovarian carcinoma (HGOC) progressing after poly(adenosine diphosphate-ribose) polymerase-inhibitor (PARPi). WEE1/CDK2-inhibitors efficacy is under investigation in HGOC harbouring CCNE1 amplification/Cyclin E1 overexpression. However, Cyclin E1 expression evolution after PARPi has not been studied. We aimed to describe Cyclin E1 expression/CCNE1 copy number in post-PARPi HGOC samples and compare to paired samples from diagnosis and/or post-neoadjuvant chemotherapy (post-NACT).

Methods

Thirty-eight patients with available post-PARPi samples were included; paired samples from diagnosis (n = 26) and/or post-NACT (n = 24) were collected. Cyclin E1 expression was quantified using immunohistochemistry (IHC). CCNE1 copy number was evaluated using fluorescent in situ hybridisation (FISH).

Results

Seventy-two percent (26/36) of HGOC were homologous recombination deficient. Intratumoral Cyclin E1 expression was homogenous in samples from synchronous but anatomically distinct tumour sites. However, Cyclin E1 expression increased significantly between diagnosis and progression post-PARPi (median H-score = 113 versus 163, respectively; p = 0.034). The proportion of Cyclin E1-high (H-score ≥ 150) tumours was 31% (8/26) at diagnosis, 42% (10/24) post-NACT, and increased significantly to 61% (23/38) post-PARPi (versus diagnosis; p = 0.024). In contrast, only 10% (2/20) of Cyclin E1-high HGOC exhibited CCNE1 amplification ( ≥ 8 CCNE1 copies).

Conclusions

Cyclin E1 expression in HGOC increases at post-PARPi progression, independently of CCNE1 amplification.